Top-Rated StocksTop-RatedNASDAQ:ENGN enGene (ENGN) Stock Price, News & Analysis $5.96 +0.13 (+2.23%) (As of 05:26 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About enGene Stock (NASDAQ:ENGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get enGene alerts:Sign Up Key Stats Today's Range$5.88▼$6.5250-Day Range$5.83▼$9.8352-Week Range$4.42▼$18.40Volume131,078 shsAverage Volume118,111 shsMarket Capitalization$263.53 millionP/E RatioN/ADividend YieldN/APrice Target$29.78Consensus RatingBuy Company OverviewenGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Read More… enGene Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks75th Percentile Overall ScoreENGN MarketRank™: enGene scored higher than 75% of companies evaluated by MarketBeat, and ranked 267th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingenGene has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageenGene has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about enGene's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for enGene are expected to decrease in the coming year, from ($1.52) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of enGene is -10.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of enGene is -10.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioenGene has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.14% of the float of enGene has been sold short.Short Interest Ratio / Days to CoverenGene has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in enGene has recently decreased by 0.14%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldenGene does not currently pay a dividend.Dividend GrowthenGene does not have a long track record of dividend growth.Read more about enGene's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.14% of the float of enGene has been sold short.Short Interest Ratio / Days to CoverenGene has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in enGene has recently decreased by 0.14%, indicating that investor sentiment is improving. News and Social Media2.3 / 5News Sentiment1.20 News SentimentenGene has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for enGene this week, compared to 22 articles on an average week.Search InterestOnly 9 people have searched for ENGN on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added enGene to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, enGene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,651,103.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.70% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about enGene's insider trading history. Receive ENGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter. Email Address ENGN Stock News HeadlinesPositive Developments in enGene Holdings’ LEGEND Trial Support Buy RatingDecember 21 at 1:24 AM | markets.businessinsider.comenGene Reports Full Year 2024 Financial Results and Provides a Business UpdateDecember 19, 2024 | financialpost.comForced out of retirement by these trades You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changedDecember 23, 2024 | DTI (Ad)enGene Reports Full Year 2024 Financial Results and Provides a Business UpdateDecember 19, 2024 | businesswire.comenGene Holdings: Compelling Early Data Bode Well For Their Near-Term OutlookDecember 15, 2024 | seekingalpha.comenGene to Participate in Upcoming Investor ConferencesNovember 25, 2024 | financialpost.comenGene to Participate in Upcoming Investor ConferencesNovember 25, 2024 | financialpost.com'Getting the engine going': Council Bluffs kickstarting housing projectsNovember 14, 2024 | msn.comSee More Headlines ENGN Stock Analysis - Frequently Asked Questions How have ENGN shares performed this year? enGene's stock was trading at $9.23 at the beginning of the year. Since then, ENGN shares have decreased by 35.4% and is now trading at $5.96. View the best growth stocks for 2024 here. How were enGene's earnings last quarter? enGene Holdings Inc. (NASDAQ:ENGN) posted its quarterly earnings data on Thursday, December, 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06. Who are enGene's major shareholders? enGene's top institutional investors include Franklin Resources Inc. (2.69%), Point72 Asset Management L.P. (1.50%) and Wolverine Asset Management LLC (0.01%). Insiders that own company stock include De Solidarite Des Travai Fonds and Growth Opportunities F Forbion. View institutional ownership trends. How do I buy shares of enGene? Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of enGene own? Based on aggregate information from My MarketBeat watchlists, some other companies that enGene investors own include PayPal (PYPL), United Microelectronics (UMC), XPeng (XPEV), Adverum Biotechnologies (ADVM), AngioDynamics (ANGO), APi Group (APG) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings12/19/2024Today12/23/2024Fiscal Year End10/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ENGN Previous SymbolNASDAQ:ENGN CUSIPN/A CIK1980845 Webwww.engene.com Phone302-273-0765FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$29.78 High Stock Price Target$40.00 Low Stock Price Target$18.00 Potential Upside/Downside+410.8%Consensus RatingBuy Rating Score (0-4)3.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-99,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-66.38% Return on Assets-56.00% Debt Debt-to-Equity Ratio0.09 Current Ratio19.52 Quick Ratio19.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$3.51 per share Price / Cash Flow1.66 Book Value$3.12 per share Price / Book1.87Miscellaneous Outstanding Shares44,216,000Free Float38,158,000Market Cap$257.78 million OptionableN/A Beta-0.78 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:ENGN) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.